Loading...
menu
Search
AI Trading Bot
Features
Markets
News
Resources
Pricing
Get Started
Home
ETF
SPRY
SPRY
-
Add to Watchlist
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
Overview
Technical
News
SPRY News
ARS Pharmaceuticals Launches New Allergy Treatment in Canada
5d ago
Newsfilter
Northland Capital Begins Coverage of ARS Pharmaceuticals Inc. with Outperform Rating and $25 Target Price
Apr 09 2026
moomoo
FDA Allows ARS Pharmaceuticals to Remove Age Requirement for Neffy
Mar 27 2026
seekingalpha
ARS Pharmaceuticals Receives FDA Approval for neffy Label Update
Mar 27 2026
NASDAQ.COM
ARS Pharma Updates neffy Dosage Guidelines for All Weights
Mar 27 2026
Newsfilter
ARS Pharmaceuticals Q4 2025 Earnings Call Insights
Mar 09 2026
seekingalpha
ARS Pharmaceuticals Reports $84.3 Million Revenue for 2025
Mar 09 2026
Newsfilter
ARS Pharmaceuticals Reports FY EPS Beat with Strong Cash Position
Mar 09 2026
seekingalpha
Breakthroughs in Gene Therapy and Needle-Free Treatment
Feb 17 2026
NASDAQ.COM
Biotech Companies' Growth Prospects
Feb 16 2026
Fool
Aquestive Therapeutics Receives Complete Response Letter from FDA
Feb 02 2026
Benzinga
ARS Pharmaceuticals Secures Expanded Authorization for EURneffy
Feb 02 2026
NASDAQ.COM
ARS Pharmaceuticals Stock Rises 18.86% Following FDA Update on Rival Aquestive
Jan 09 2026
Benzinga
Aquestive Therapeutics Faces 40% Stock Drop After FDA Identifies Deficiencies in Anaphylm NDA
Jan 09 2026
Benzinga
ARS Pharma's Neffy Approved in China for Allergy Treatment
Jan 02 2026
NASDAQ.COM
ARS Pharma's neffy Approved as First Community Use Epinephrine Product in China
Dec 29 2025
Globenewswire
Show More News
